Pirmitegravir

DB18974InvestigationalSmall molecule

Pirmitegravir is under investigation in clinical trial NCT05869643 (A Clinical Trial of STP0404 in Treatment-naïve Adults With HIV-1 Infection).

Mechanism: Pharmacologically active on Gag-Pol polyprotein
Curator reviewed
Formula / weight: C₂₇H₃₁ClN₄O₃ · 495.02 g/mol (avg)
Also known as: (αS)-4-(4-Chlorophenyl)-α-(1,1-dimethylethoxy)-2,3,6-trimethyl-1-[(1-methyl-1H-pyrazol-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridine-5-acetic acid · 1H-Pyrrolo[2,3-b]pyridine-5-acetic acid, 4-(4-chlorophenyl)-α-(1,1-dimethylethoxy)-2,3,6-trimethyl-1-[(1-methyl-1H-pyrazol-4-yl)methyl]-, (αS)-
Code names: STP-0404

Resolves to

Compound

Structure

InChIKeyGNRDGAWRAIJOSU-DEOSSOPVSA-NSMILESCN1C=C(CN2C(C)=C(C)C3=C(C4=CC=C(Cl)C=C4)C([C@H](OC(C)(C)C)C(O)=O)=C(C)N=C23)C=N1

Targets

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pirmitegravir, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.